Journal of VitreoRetinal Diseases最新文献

筛选
英文 中文
Intravitreal Aflibercept With vs Without Pneumatic Displacement for Submacular Hemorrhage Associated With Polypoidal Choroidal Vasculopathy. 玻璃体内注射阿非利塞联合与不加气压置换治疗伴息肉样脉络膜血管病变的黄斑下出血。
IF 0.5
Journal of VitreoRetinal Diseases Pub Date : 2025-04-25 DOI: 10.1177/24741264251335629
Taku Wakabayashi, Chikako Hara, Akihiko Shiraki, Nobuhiko Shiraki, Yoko Fukushima, Susumu Sakimoto, Kaori Sayanagi, Kentaro Nishida, Shigeru Sato, Hirokazu Sakaguchi, Kohji Nishida
{"title":"Intravitreal Aflibercept With vs Without Pneumatic Displacement for Submacular Hemorrhage Associated With Polypoidal Choroidal Vasculopathy.","authors":"Taku Wakabayashi, Chikako Hara, Akihiko Shiraki, Nobuhiko Shiraki, Yoko Fukushima, Susumu Sakimoto, Kaori Sayanagi, Kentaro Nishida, Shigeru Sato, Hirokazu Sakaguchi, Kohji Nishida","doi":"10.1177/24741264251335629","DOIUrl":"https://doi.org/10.1177/24741264251335629","url":null,"abstract":"<p><p><b>Purpose:</b> To compare the visual outcomes of intravitreal (IVT) aflibercept with pneumatic displacement vs without pneumatic displacement for submacular hemorrhage (SMH) associated with polypoidal choroidal vasculopathy (PCV). <b>Methods:</b> This retrospective study assessed patients with SMH associated with PCV who were treated with aflibercept and pneumatic displacement with gas (aflibercept+gas group) or with aflibercept alone (monotherapy group). Patients were followed for at least 12 months, with the best-corrected visual acuity (BCVA) at 12 months the primary outcome measure. <b>Results:</b> Forty-seven eyes of 47 patients were retrospectively analyzed from August 2013 to March 2023. The aflibercept+gas group comprised 25 eyes and the monotherapy group, 22 eyes. The 2 groups had comparable baseline characteristics. The mean logMAR best-corrected visual acuity (BCVA) before treatment was 0.78 ± 0.46 in the aflibercept+gas group and 0.83 ± 0.66 in the monotherapy group (<i>P</i> = .76). The mean BCVA (0.26 ± 0.42 vs 0.85 ± 0.57) and the mean change in (-0.52 ± 0.55 vs 0.02 ± 0.75) 12 months postoperatively was significantly better in the aflibercept+gas group than in the monotherapy group (<i>P</i> < .001 and <i>P</i> < .008, respectively). The BCVA improved by 3 or more lines in 60.0% of eyes in the aflibercept+gas group but in only 18.2% of eyes in the monotherapy group. Vitreous hemorrhage developed in 16.0% of eyes in the aflibercept+gas group and in 13.6% of eyes in the monotherapy group and retinal detachment in 4.0% and 0%, respectively (both <i>P</i> = 1.000). <b>Conclusions:</b> Better visual outcomes were achieved with IVT aflibercept and pneumatic displacement than with aflibercept alone for SMH associated with PCV.</p>","PeriodicalId":17919,"journal":{"name":"Journal of VitreoRetinal Diseases","volume":" ","pages":"24741264251335629"},"PeriodicalIF":0.5,"publicationDate":"2025-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12031733/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143971458","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cancer-Associated Retinopathy Presenting as Panuveitis Secondary to Minimally Invasive Follicular Thyroid Carcinoma. 肿瘤相关视网膜病变表现为微创滤泡性甲状腺癌继发的全葡萄膜炎。
IF 0.5
Journal of VitreoRetinal Diseases Pub Date : 2025-04-25 DOI: 10.1177/24741264251337108
Natalie Arnold, Amit Mishra, Mark Seamone
{"title":"Cancer-Associated Retinopathy Presenting as Panuveitis Secondary to Minimally Invasive Follicular Thyroid Carcinoma.","authors":"Natalie Arnold, Amit Mishra, Mark Seamone","doi":"10.1177/24741264251337108","DOIUrl":"https://doi.org/10.1177/24741264251337108","url":null,"abstract":"<p><p><b>Purpose:</b> To describe a case of cancer-associated retinopathy (CAR) secondary to follicular thyroid carcinoma. <b>Methods:</b> A single retrospective case was evaluated. <b>Results:</b> A 68-year-old woman presented with floaters and decreased vision in the right eye and was found to have panuveitis. The left eye subsequently developed panuveitis 6 months later, ultimately resulting in retinal atrophy. Extensive investigations, including vitreous biopsies, imaging, and positron emission tomography, led to a diagnosis of CAR secondary to minimally invasive follicular thyroid carcinoma with serology positive for anti-enolase, anti-HSP60, and anti-glyceraldehyde-3-phosphate dehydrogenase. <b>Conclusions:</b> Cases of CAR secondary to minimally invasive follicular thyroid carcinoma are rare. Ensuring an early diagnosis and promptly initiating treatment, with a goal of preserving sight, are imperative.</p>","PeriodicalId":17919,"journal":{"name":"Journal of VitreoRetinal Diseases","volume":" ","pages":"24741264251337108"},"PeriodicalIF":0.5,"publicationDate":"2025-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12031738/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144033815","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Early Treatment in Patients With Small and Medium-Small Class 2 Gene Expression Profiling Uveal Melanoma to Reduce Mortality. 早期治疗中小2类基因表达谱葡萄膜黑色素瘤可降低死亡率。
IF 0.5
Journal of VitreoRetinal Diseases Pub Date : 2025-04-25 DOI: 10.1177/24741264251337101
Natalia C González, Victor M Villegas, Aaron S Gold, Azeema Latiff, Timothy G Murray
{"title":"Early Treatment in Patients With Small and Medium-Small Class 2 Gene Expression Profiling Uveal Melanoma to Reduce Mortality.","authors":"Natalia C González, Victor M Villegas, Aaron S Gold, Azeema Latiff, Timothy G Murray","doi":"10.1177/24741264251337101","DOIUrl":"https://doi.org/10.1177/24741264251337101","url":null,"abstract":"<p><p><b>Purpose:</b> To evaluate the class 2 gene expression profiling of patients with small and medium-small uveal melanoma, focusing on tumor control, metastases, and mortality. <b>Methods:</b> This retrospective case series evaluated patients treated for small or medium-small uveal melanoma by the same surgeon. Patients with small uveal melanoma were treated with microincision vitrectomy surgery or brachytherapy, and patients with medium-small uveal melanoma were treated with brachytherapy. All patients were gene expression profiling class 2. <b>Results:</b> Forty-two patients (21 with a diagnosis of small melanoma; 21 with a diagnosis of medium-small melanoma) with a mean age of 58 years and a confirmed diagnosis of class 2 gene expression profiling melanoma were identified. The melanoma-specific mortality at the 5-year follow-up was 4.8% (1/21) for patients with small melanoma and 14.3% (3/21) for patients with medium-small melanoma. The rate of melanoma-specific active metastasis at 5 years was 4.8% (1/21) for patients with small melanoma and 14.3% (3/21) for patients with medium-small melanoma. In both groups, the enucleation rate at 5 years was 0%. <b>Conclusions:</b> Small tumor management achieves excellent anatomic and visual outcomes but mandates diagnostic accuracy and defined long-term outcomes as well as follow-up (5-year minimum in this series). Gene expression profiling classification is important in prognostication; however, early treatment of small tumors significantly decreases the predicted mortality and has the greatest potential effect on patient survival, even for class 2 melanomas.</p>","PeriodicalId":17919,"journal":{"name":"Journal of VitreoRetinal Diseases","volume":" ","pages":"24741264251337101"},"PeriodicalIF":0.5,"publicationDate":"2025-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12031732/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143970963","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Bilateral Sterile Granulomatous Uveitis Caused by Intravitreal Injections of Faricimab. 法瑞昔单抗玻璃体内注射引起双侧无菌性肉芽肿性葡萄膜炎。
IF 0.5
Journal of VitreoRetinal Diseases Pub Date : 2025-04-21 DOI: 10.1177/24741264251330339
Christine Hill, Dimitrios C Arhontoulis, Huyen Bui, Sarah M DeVaro, Peter H Tang
{"title":"Bilateral Sterile Granulomatous Uveitis Caused by Intravitreal Injections of Faricimab.","authors":"Christine Hill, Dimitrios C Arhontoulis, Huyen Bui, Sarah M DeVaro, Peter H Tang","doi":"10.1177/24741264251330339","DOIUrl":"https://doi.org/10.1177/24741264251330339","url":null,"abstract":"<p><p><b>Purpose:</b> To describe a case of severe bilateral granulomatous uveitis caused by treatment with faricimab. <b>Methods:</b> A single case was reviewed. <b>Results:</b> A 79-year-old woman with diabetic macular edema developed severe uveitis OU 16 days after bilateral intravitreal (IVT) injections of faricimab. The patient's visual acuity (VA) was hand motions OD and 20/400 OS. She refused IVT antibiotics at bedside but consented to an emergency pars plana vitrectomy (PPV) OU. The laboratory workup for infectious and autoimmune etiologies was unremarkable, as were bacterial and fungal cultures from the PPV. High-dose systemic steroids were initiated after surgery. The patient's VA recovered to 20/30 OD and 20/25 OS. <b>Conclusions:</b> Reports of severe uveitis resulting from injections of faricimab have been documented. We describe a unique case in which the patient with granulomatous uveitis OU experienced a significant decline in vision. With high-dose systemic steroid therapy and surgical intervention, her VA recovered to near baseline.</p>","PeriodicalId":17919,"journal":{"name":"Journal of VitreoRetinal Diseases","volume":" ","pages":"24741264251330339"},"PeriodicalIF":0.5,"publicationDate":"2025-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12012491/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143989554","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Intraocular Inflammation, Safety Events, and Outcomes After Intravitreal Injection of Ranibizumab, Aflibercept, Brolucizumab, Abicipar Pegol, and Faricimab for nAMD. 玻璃体腔内注射雷尼单抗、阿非利塞普、Brolucizumab、Abicipar Pegol和Faricimab治疗nAMD后的眼内炎症、安全事件和结果。
IF 0.5
Journal of VitreoRetinal Diseases Pub Date : 2025-04-21 DOI: 10.1177/24741264251332515
Marta Stevanovic, Nicole Koulisis, Tom Chen, Stavros N Moysidis, Bruce Burkemper, Brian C Toy, Narsing A Rao, Dean Eliott, Mark S Humayun
{"title":"Intraocular Inflammation, Safety Events, and Outcomes After Intravitreal Injection of Ranibizumab, Aflibercept, Brolucizumab, Abicipar Pegol, and Faricimab for nAMD.","authors":"Marta Stevanovic, Nicole Koulisis, Tom Chen, Stavros N Moysidis, Bruce Burkemper, Brian C Toy, Narsing A Rao, Dean Eliott, Mark S Humayun","doi":"10.1177/24741264251332515","DOIUrl":"https://doi.org/10.1177/24741264251332515","url":null,"abstract":"<p><p><b>Purpose:</b> To compare the rates of intraocular inflammation (IOI) in patients with neovascular age-related macular degeneration (nAMD) after injection of intravitreal (IVT) antivascular endothelial growth factor drugs. <b>Methods:</b> This study included all phase 3 randomized clinical trials of patients with nAMD treated with ranibizumab, aflibercept, brolucizumab, abicipar pegol, or faricimab. The outcomes assessed were the incidence of IOI, retinal artery occlusion (RAO), retinal vasculitis and choroiditis, endophthalmitis, and serious systemic adverse events (AEs) as well as the change in visual acuity (VA) (Early Treatment Diabetic Retinopathy Study letters) and in central retinal thickness (CRT). <b>Results:</b> Abicipar pegol was associated with a higher incidence of IOI than aflibercept, ranibizumab, faricimab, and sham injections, while brolucizumab was associated with a higher rate of IOI than aflibercept, faricimab, and sham injections. Abicipar pegol was also associated with a higher rate of endophthalmitis than aflibercept. Significantly more retinal vasculitis and choroiditis was seen with abicipar pegol and brolucizumab than with ranibizumab and aflibercept, respectively, and RAOs occurred more frequently with abicipar pegol and brolucizumab than with ranibizumab and aflibercept, respectively. There were no differences in the change in VA among the drugs. Treatment with brolucizumab resulted in a greater change in CRT than with abicipar pegol, aflibercept, ranibizumab, and faricimab, while treatment with faricimab resulted in a greater change in CRT than aflibercept and ranibizumab. Faricimab was associated with fewer serious systemic AEs than aflibercept. <b>Conclusions:</b> Abicipar pegol and brolucizumab were associated with a higher incidence of ocular AEs in phase 3 randomized controlled trials. The potential benefits of these drugs should be weighed against the AEs.</p>","PeriodicalId":17919,"journal":{"name":"Journal of VitreoRetinal Diseases","volume":" ","pages":"24741264251332515"},"PeriodicalIF":0.5,"publicationDate":"2025-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12012493/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144042611","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Peer-Review Essentials: Reviewing Manuscripts for the Journal of VitreoRetinal Diseases. 同行评议要点:《玻璃体视网膜疾病杂志》审稿。
IF 0.5
Journal of VitreoRetinal Diseases Pub Date : 2025-04-15 DOI: 10.1177/24741264251331647
Eric Jung, Aleksandra Rachitskaya, Yoshihiro Yonekawa, Timothy G Murray
{"title":"Peer-Review Essentials: Reviewing Manuscripts for the <i>Journal of VitreoRetinal Diseases</i>.","authors":"Eric Jung, Aleksandra Rachitskaya, Yoshihiro Yonekawa, Timothy G Murray","doi":"10.1177/24741264251331647","DOIUrl":"https://doi.org/10.1177/24741264251331647","url":null,"abstract":"<p><p>The thoughtful process of peer review allows for the vetting and improvement of scientific work that leads to quality research and, eventually, advancement of the field of retina. Progress in medicine would not occur without dedicated researchers, but just as important are the peer reviewers who take the time assess their work, weigh in on their validity, and help bring these papers to life. Here, we discuss how to effectively review a journal manuscript in a way that helps both the beginning reviewer and the seasoned expert develop a framework to provide meaningful peer review. Although this guide was specifically written with <i>JVRD</i> aims in mind, these suggestions can be broadly applied to the process of manuscript review in general.</p>","PeriodicalId":17919,"journal":{"name":"Journal of VitreoRetinal Diseases","volume":" ","pages":"24741264251331647"},"PeriodicalIF":0.5,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11999991/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144029770","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Multiple Successive Branch Retinal Artery Occlusions in a Patient With Antiphospholipid Syndrome Despite Anticoagulation. 尽管抗凝治疗,抗磷脂综合征患者的多个连续视网膜分支动脉闭塞。
IF 0.5
Journal of VitreoRetinal Diseases Pub Date : 2025-04-12 DOI: 10.1177/24741264251331638
Samantha R Goldburg, Albert S Li
{"title":"Multiple Successive Branch Retinal Artery Occlusions in a Patient With Antiphospholipid Syndrome Despite Anticoagulation.","authors":"Samantha R Goldburg, Albert S Li","doi":"10.1177/24741264251331638","DOIUrl":"https://doi.org/10.1177/24741264251331638","url":null,"abstract":"<p><p><b>Purpose:</b> To describe a patient with antiphospholipid syndrome presenting with branch retinal artery occlusions (BRAO) despite anticoagulation. <b>Methods:</b> A single case was evaluated. <b>Results:</b> A 53-year-old woman with antiphospholipid syndrome on anticoagulation presented for a routine ophthalmic examination. She had no visual complaints, and the visual acuity was 20/25<sup>-1</sup> OD and 20/30<sup>-1</sup> OS. A BRAO was found in the right eye. Despite treatment with aspirin, warfarin, prednisone, plasmapheresis, and rituximab, multiple new occlusions were found when the patient returned the next month. She ultimately had a stroke, which led to her death. <b>Conclusions:</b> This case underscores the importance of interdisciplinary care for patients with antiphospholipid syndrome presenting with BRAOs despite anticoagulation.</p>","PeriodicalId":17919,"journal":{"name":"Journal of VitreoRetinal Diseases","volume":" ","pages":"24741264251331638"},"PeriodicalIF":0.5,"publicationDate":"2025-04-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11994628/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144030055","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Switch to Aflibercept After Chronic Treatment With Bevacizumab for Choroidal Neovascularization With Age-Related Macular Degeneration. 贝伐单抗慢性治疗脉络膜新生血管伴老年性黄斑变性后改用阿非利塞普。
IF 0.5
Journal of VitreoRetinal Diseases Pub Date : 2025-04-12 DOI: 10.1177/24741264251330334
Zofia Anna Nawrocka, Karolina Dulczewska-Cichecka, Michal Zając, Thomas A Galus, Magdalena Trębinska, Jerzy Nawrocki
{"title":"Switch to Aflibercept After Chronic Treatment With Bevacizumab for Choroidal Neovascularization With Age-Related Macular Degeneration.","authors":"Zofia Anna Nawrocka, Karolina Dulczewska-Cichecka, Michal Zając, Thomas A Galus, Magdalena Trębinska, Jerzy Nawrocki","doi":"10.1177/24741264251330334","DOIUrl":"https://doi.org/10.1177/24741264251330334","url":null,"abstract":"<p><p><b>Purpose:</b> To present the 5-year anatomic and functional outcomes in patients with choroidal neovascularization (CNV) and age-related macular degeneration (AMD) and determine whether late-onset intensification of treatment results in improved outcomes. <b>Methods:</b> This retrospective interventional study analyzed spectral-domain optical coherence tomography data and visual acuity (VA) in eyes where treatment intensification was implemented after a mean of 39 months. Data collected included age, sex, injection frequency, central retinal thickness, type of CNV, and VA. Patients were evaluated every 4 to 10 weeks, depending on the disease activity. <b>Results:</b> Fifty eyes of 50 patients with CNV were evaluated. The mean initial VA was 0.37 Snellen (0.58 logMAR), which improved to 0.44 Snellen (0.47 logMAR) after the first bevacizumab injection. Six months after bevacizumab was switched to aflibercept, the improvement in VA was significant in all groups (<i>P</i> < .05). The VA improved throughout the 6-year observation period, with the greatest improvement in VA after the switch seen in patients who received the most injections (<i>P</i> < .05), had the best initial VA (<i>P</i> < .05), and who experienced a significantly greater improvement in VA after the first bevacizumab injection (<i>P</i> = .01). <b>Conclusions:</b> Increasing the treatment frequency, even after several years of treatment, improved visual outcomes in patients with CNV and AMD who switched from bevacizumab to aflibercept.</p>","PeriodicalId":17919,"journal":{"name":"Journal of VitreoRetinal Diseases","volume":" ","pages":"24741264251330334"},"PeriodicalIF":0.5,"publicationDate":"2025-04-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11993555/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144033596","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Possible Association Between Dopamine Antagonists and Increased Conversion to Exudative Age-Related Macular Degeneration. 多巴胺拮抗剂与向渗出性老年性黄斑变性转变增加之间的可能关联。
IF 0.5
Journal of VitreoRetinal Diseases Pub Date : 2025-04-02 DOI: 10.1177/24741264251330338
Peter J Weng, Richard Morgan, Dilraj S Grewal, Sharon Fekrat
{"title":"Possible Association Between Dopamine Antagonists and Increased Conversion to Exudative Age-Related Macular Degeneration.","authors":"Peter J Weng, Richard Morgan, Dilraj S Grewal, Sharon Fekrat","doi":"10.1177/24741264251330338","DOIUrl":"10.1177/24741264251330338","url":null,"abstract":"<p><p><b>Purpose:</b> To investigate whether modulating dopamine signaling affects conversion to exudative age-related macular degeneration (AMD). <b>Methods:</b> A retrospective cohort study was performed using the Duke Epic database. Eyes from patients with a diagnosis of nonexudative AMD with at least 1 year of follow-up were evaluated for conversion to exudative AMD. Eyes with an AMD diagnosis were evaluated for age, sex, smoking history, hypertension, Age-Related Eye Disease Study (AREDS) or AREDS2 prescription, dopamine-modulating therapy prescription, and indication for dopamine-modulating therapy. Generalized estimating equations were used to calculate odds ratios for individual variables on conversion from nonexudative to exudative AMD. <b>Results:</b> Five hundred fifty-eight eyes of 354 patients with an initial diagnosis of nonexudative AMD were evaluated for conversion to exudative AMD. Conversion to exudative AMD was significantly higher in patients who had been on dopamine antagonist therapies for at least 3 years than in patients who were not on any dopamine-modulating therapies. After controlling for other variables, dopamine antagonists were associated with an increased risk for conversion to exudative AMD at 3 years of follow-up (<i>P</i> = .005). <b>Conclusions:</b> These findings suggest that antagonizing dopamine signaling may be associated with the development of macular neovascularization in eyes with nonexudative AMD. Although the data are observational, these findings warrant further investigation of dopamine signaling in conversion to exudative AMD.</p>","PeriodicalId":17919,"journal":{"name":"Journal of VitreoRetinal Diseases","volume":" ","pages":"24741264251330338"},"PeriodicalIF":0.5,"publicationDate":"2025-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11966630/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143795769","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Postoperative Methotrexate to Reduce Reoperation Rate and Improve Vision in Patients With Complex Retinal Detachments, Advanced Diabetic Retinopathy, and Trauma. 术后甲氨蝶呤对复杂性视网膜脱离、晚期糖尿病视网膜病变和创伤患者降低再手术率和改善视力的作用。
IF 0.5
Journal of VitreoRetinal Diseases Pub Date : 2025-03-18 DOI: 10.1177/24741264251323305
Lauren Gibson, Alyson Nguyen, Jared Ridgeway, Mariam Omar, Christopher Purvis, Yazen Shihab, Christopher D Riemann, Alan J Franklin
{"title":"Postoperative Methotrexate to Reduce Reoperation Rate and Improve Vision in Patients With Complex Retinal Detachments, Advanced Diabetic Retinopathy, and Trauma.","authors":"Lauren Gibson, Alyson Nguyen, Jared Ridgeway, Mariam Omar, Christopher Purvis, Yazen Shihab, Christopher D Riemann, Alan J Franklin","doi":"10.1177/24741264251323305","DOIUrl":"10.1177/24741264251323305","url":null,"abstract":"<p><p><b>Purpose:</b> To identify the potential benefits of postoperative intravitreal (IVT) methotrexate (MTX) for proliferative vitreoretinopathy (PVR), trauma, or advanced diabetic retinopathy (DR). <b>Methods:</b> A retrospective chart review was performed of previously unoperated eyes at high risk for failure as a result of preexisting PVR, trauma, or advanced DR. Patients were included who had retinal detachment (RD) surgery for the following reasons: failed previous retinal reattachment surgery, advanced proliferative DR (PDR), initial surgery for RD associated with trauma, or primary RD associated with grade C PVR. MTX 200 to 400 µg was administered intravitreally at postoperative weeks 1, 2, 4, 7, and 11. Data analyzed included the reoperation rate, visual acuity (VA), physical examination findings, and optical coherence tomography biomarkers. <b>Results:</b> Of the 255 eyes evaluated, 94 received IVT MTX (MTX group) and 161 eyes did not (control group). The mean number of reoperations was 0.39 in the MTX group and 0.94 in the control group (<i>P</i> < .01). The MTX group had a mean gain in VA of 1 line, while the control group had a mean loss of 2.9 lines (<i>P</i> < .01). <b>Conclusions:</b> Postoperative IVT MTX in eyes with advanced PDR or complicated RD yields comparable effective results, including reduced reoperation rates and improved VA.</p>","PeriodicalId":17919,"journal":{"name":"Journal of VitreoRetinal Diseases","volume":" ","pages":"24741264251323305"},"PeriodicalIF":0.5,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11915221/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143663883","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信